Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality

@inproceedings{Pircher2017SynergiesOT,
  title={Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality},
  author={Andreas Pircher and Dominik Georg Friedrich Wolf and Axel Heidenreich and Wolfgang Hilbe and Renate Pichler and Isabel Heidegger},
  booktitle={International journal of molecular sciences},
  year={2017}
}
In recent years, considerable advances concerning therapeutic strategies in patients with metastatic cancer have been achieved. Particularly in renal cell cancer (RCC) and advanced stage non-small cell lung cancer (NSCLC), immune-activating and antiangiogenic (AA) drugs (i.e., checkpoint antibodies and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR) targeting compounds, respectively) have been successfully developed. As immune-effector cells have to enter the tumor, it is… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

A phase I / II study to assess the safety and efficacy of pazopanib ( PAZ ) and pembrolizumab ( PEM ) in patients ( pts ) with advanced renal cell carcinoma ( aRCC )

S. Chowdhury, D. F. McDermott, +6 authors J. R. Infante
  • J . Clin . Oncol .
  • 2017

A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma

S. Chowdhury, D. F. McDermott, +6 authors J. R. Infante
  • (aRCC). J. Clin. Oncol
  • 2017
VIEW 2 EXCERPTS

A phase II study of atezolizumab ( atezo ) with or without bevacizumab ( bev ) versus sunitinib ( sun ) in untreated metastatic renal cell carcinoma ( mRCC ) patients ( pts )

D. F. McDermott, M. B. Atkins, +7 authors J. D. Hainsworth
  • J . Clin . Oncol .
  • 2017

A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients

D. F. McDermott, M. B. Atkins, +7 authors J. D Hainsworth
  • (pts). J. Clin. Oncol
  • 2017
VIEW 1 EXCERPT

CD 4 + T cell activation and vascular normalization : Two sides of the same coin ?

R. L. Siegel, K. D. Miller, A. Jemal
  • Immunity
  • 2017

CD4+ T cell activation and vascular normalization: Two sides of the same coin? Immunity

M. De Palma, R. K. Jain
  • 2017
VIEW 2 EXCERPTS